EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

THE ROLE OF MOLECULAR PROFILING IN SELECTING A COMBINED TREATMENT STRATEGY FOR EPITHELIAL OVARIAN CANCER

Iryna Hrytsay, Nataliia Volodko

Acta Medica Leopoliensia · 22.12.2025 · 31 (3-4) · 138-152

DOI: 10.25040/aml2025.3-4.138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Medica Leopoliensia, online erschienen am 22.12.2025. Verfasst von Iryna Hrytsay und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the impact of molecular profiling on the choice of combined treatment strategy and clinical outcomes in patients with epithelial ovarian cancer. Materials and Methods. The study included 88 patients with stage IIIC-IV epithelial ovarian cancer, divided into two groups. In the first group (n=44), immunohistochemical and molecular genetic profiling was performed to determine HRD status and mutations in the BRCA1/2 and TP53 genes, in addition to standard clinical and instrumental examinations. Based on these results, an individualized treatment strategy was developed and implemented. In the second group (n=44), without molecular profiling, the standard treatment regimen was applied without molecular profiling. The groups were comparable in age, stages, and histological tumor subtypes. Treatment efficacy was assessed by computed tomography (CT) 3 months after treatment, and survival analysis was performed using the Kaplan-Meier method.

Results

Personalized selection of treatment strategy led to improved survival. The recurrence rate was significantly lower in patients with molecular profiling (61.36% versus 84.09%, p=0.02). Absence of radiological signs of recurrence on CT was more frequently observed in the first group (45.45% versus 20.45%, p=0.013), whereas disease progression predominated in the second group. Five-year survival in the molecular profiling group was 63% compared to 33% in the standard treatment group, with a median survival of 95 and 36 months, respectively (p

Zitieren

APA

Hrytsay, I., & Volodko, N. (2025). THE ROLE OF MOLECULAR PROFILING IN SELECTING A COMBINED TREATMENT STRATEGY FOR EPITHELIAL OVARIAN CANCER. Acta Medica Leopoliensia, 31(3-4), 138-152. https://doi.org/10.25040/aml2025.3-4.138

Vancouver

Hrytsay I, Volodko N. THE ROLE OF MOLECULAR PROFILING IN SELECTING A COMBINED TREATMENT STRATEGY FOR EPITHELIAL OVARIAN CANCER. Acta Medica Leopoliensia. 2025;31(3-4):138-152. doi:10.25040/aml2025.3-4.138

BibTeX
@article{Hrytsay2025,
  author = {Hrytsay, Iryna and Volodko, Nataliia},
  title = {THE ROLE OF MOLECULAR PROFILING IN SELECTING A COMBINED TREATMENT STRATEGY FOR EPITHELIAL OVARIAN CANCER},
  journal = {Acta Medica Leopoliensia},
  year = {2025},
  volume = {31},
  number = {3-4},
  pages = {138--152},
  doi = {10.25040/aml2025.3-4.138}
}
Kostenlos starten →